Zacks Investment Research downgraded shares of CARDICA INC (CRDC) from N/A to NEUTRAL on July 19, 2013, with a target price of $1.50.
Cardica, Inc. designs and manufactures proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass graft surgery. In these surgery procedures, veins or arteries are used to construct alternative conduits to restore blood flow beyond narrowed or occluded portions of coronary arteries, bypassing the narrowed or occluded portion of the artery that is impairing blood flow to the heart muscle. Our first two products, the C-Port Distal Anastomosis System, and the PAS-Port Proximal Anastomosis System, provide cardiovascular surgeons with easy-to-use automated systems to perform consistent, rapid and reliable connections, or anastomoses, of the vessels, which surgeons generally view as the most critical aspect of the bypass procedure.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CARDICA INC (CRDC),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment